Prescribed Reading: Novartis ups the ante in gene therapy, while GSK folds on the space – BioPharma Dive
|
Prescribed Reading: Novartis ups the ante in gene therapy, while GSK folds on the space
BioPharma Dive The M&A bonanza of 2018 continued in earnest this week, with Novartis AG plopping down more than $8 billion for a gene therapy company and Alexion Pharmaceuticals Inc. finally forking over some dough to add to its pipeline. Novartis is going full force … |
